However, relapse of leukemia through CD19 loss variants in leukemia/lymphoma patients and immunosuppressive microenvironment or lack of tumor-associated antigens (TAAs) in solid tumors (9–11) represents major challenges for CAR T cell therapies. This evidence concerns the gene CD19 and leukemia.